Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

  • Alteration of p53 damage response by tamoxifen treatment.
    C Guillot, N Falette, S Courtois, T Voeltzel, E Garcia, M Ozturk and A Puisieux
    Clin Cancer Res September 1 1996 2 (9) 1439-1444;

  • Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
    J T Pinto, B P Suffoletto, T M Berzin, C H Qiao, S Lin, W P Tong, F May, B Mukherjee and W D Heston
    Clin Cancer Res September 1 1996 2 (9) 1445-1451;

  • Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
    H D Preisler, V M Kotelnikov, S LaFollette, S Taylor 4th, S Mundle, N Wood, J S Coon 4th, J Hutchinson, W Panje, D D Caldarelli and K Griem
    Clin Cancer Res September 1 1996 2 (9) 1453-1460;

  • Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    F M Muggia, X Wu, D Spicer, S Groshen, S Jeffers, C G Leichman, L Leichman and K K Chan
    Clin Cancer Res September 1 1996 2 (9) 1461-1467;

  • Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial.
    K H Link, M Kornmann, G H Leder, U Butzer, J Pillasch, L Staib, F Gansauge and H G Beger
    Clin Cancer Res September 1 1996 2 (9) 1469-1474;

  • Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
    J L Marshall, E Richmond and R J DeLap
    Clin Cancer Res September 1 1996 2 (9) 1475-1480;

  • Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    L W Anderson, T L Chen, O M Colvin, L B Grochow, J M Collins, M J Kennedy and J M Strong
    Clin Cancer Res September 1 1996 2 (9) 1481-1487;

  • Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    J L Abbruzzese, T Madden, S M Sugarman, A L Ellis, S Loughlin, K R Hess, R A Newman, L A Zwelling and M N Raber
    Clin Cancer Res September 1 1996 2 (9) 1489-1497;

  • Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation.
    H S Chan, G DeBoer, J J Thiessen, A Budning, J E Kingston, J M O'Brien, G Koren, E Giesbrecht, G Haddad, Z Verjee, J L Hungerford, V Ling and B L Gallie
    Clin Cancer Res September 1 1996 2 (9) 1499-1508;

  • Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    J D Bitran, B Samuels, Y Trujillo, L Klein, L Schroeder and J Martinec
    Clin Cancer Res September 1 1996 2 (9) 1509-1513;

  • Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
    S Lundgren, S I Helle and P E Lonning
    Clin Cancer Res September 1 1996 2 (9) 1515-1521;

  • Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    U Scherf, I Benhar, K O Webber, I Pastan and U Brinkmann
    Clin Cancer Res September 1 1996 2 (9) 1523-1531;

  • Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
    Y Messinger, Y Yanishevski, V I Avramis, O Ek, L M Chelstrom, R Gunther, D E Myers, J D Irvin, W Evans and F M Uckun
    Clin Cancer Res September 1 1996 2 (9) 1533-1542;

  • The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases.
    B Dezso, G P Haas, F Hamzavi, S Kim, E J Montecillo, P D Benson, J E Pontes, R L Maughan and G G Hillman
    Clin Cancer Res September 1 1996 2 (9) 1543-1552;

  • Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression.
    R Y Wang, P Troncoso, J L Palmer, A K El-Naggar and J C Liang
    Clin Cancer Res September 1 1996 2 (9) 1553-1558;

  • Correlation of chromosome 17p loss with clinical outcome in medulloblastoma.
    S M Emadian, J D McDonald, S C Gerken and D Fults
    Clin Cancer Res September 1 1996 2 (9) 1559-1564;

  • Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    A Gerl, R Lamerz, C Clemm, K Mann, R Hartenstein and W Wilmanns
    Clin Cancer Res September 1 1996 2 (9) 1565-1570;

  • Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.
    A A Elbendary, F D Cirisano, A C Evans Jr, P L Davis, J D Iglehart, J R Marks and A Berchuck
    Clin Cancer Res September 1 1996 2 (9) 1571-1575;

  • Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer.
    O Gallo, I Chiarelli, S Bianchi, A Calzolari, L Simonetti and B Porfirio
    Clin Cancer Res September 1 1996 2 (9) 1577-1582;

  • Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia.
    J H Ohyashiki, K Ohyashiki, S Aizawa, K Kawakubo, T Shimamoto, H Iwama, S Hayashi and K Toyama
    Clin Cancer Res September 1 1996 2 (9) 1583-1589;

  • Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.
    O Caffo, C Doglioni, S Veronese, M Bonzanini, A Marchetti, F Buttitta, P Fina, R Leek, L Morelli, P D Palma, A L Harris and M Barbareschi
    Clin Cancer Res September 1 1996 2 (9) 1591-1599;

  • Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion.
    C Noviello, F Courjal and C Theillet
    Clin Cancer Res September 1 1996 2 (9) 1601-1606;

  • Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.
    V Abetamann, H F Kern and H P Elsässer
    Clin Cancer Res September 1 1996 2 (9) 1607-1618;

  • Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma.
    J Li, Y Yang, T Fujie, K Baba, H Ueo, M Mori and T Akiyoshi
    Clin Cancer Res September 1 1996 2 (9) 1619-1625;

  • Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
    C A Pettaway, S Pathak, G Greene, E Ramirez, M R Wilson, J J Killion and I J Fidler
    Clin Cancer Res September 1 1996 2 (9) 1627-1636;

Back to top
PreviousNext
September 1996
Volume 2, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Advertisement
  • Most Cited
  • Most Read
Loading
  • Immune Checkpoint Blockade Requires Macrophage CXCL9/CXCL10
  • PDAC and GATA6 Expression
  • Characterization of Glioblastoma Patient-Derived Xenografts
  • Guadecitabine and Carboplatin in Ovarian Cancer
  • Toxicity Management Affects Checkpoint Inhibitor Efficacy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement